Orilissa and Weight increased - a phase IV clinical study of FDA data

Summary:

Weight increased is reported as a side effect among people who take Orilissa (elagolix sodium), especially for people who are female, 20-29 old, have been taking the drug for < 1 month also take Lupron Depot, and have Endometriosis.

The phase IV clinical study analyzes which people have Weight increased when taking Orilissa. It is created by eHealthMe based on reports of 3,300 people who have side effects when taking Orilissa from the FDA, and is updated regularly.

What is Orilissa?

Orilissa has active ingredients of elagolix sodium. eHealthMe is studying from 3,314 Orilissa users. Check the latest studies of Orilissa.

What is Weight increased?

Weight increased is found to be associated with 2,886 drugs and 3,952 conditions by eHealthMe. Check the latest studies of Weight increased.

On Jul, 15, 2026

3,300 people reported to have side effects when taking Orilissa.
Among them, 78 people (2.36%) have Weight increased.

Among these 78 people:

How long have people been on Orilissa when they have Weight increased? *

What is the gender of people who have Weight increased when taking Orilissa? *

female: 100 %
male: 0.0 %

What is the age of people who have Weight increased when taking Orilissa? *

What are other drugs people take besides Orilissa? *

What are other side effects people have besides Weight increased? *

Hot Flush (sudden feelings of heat): 14 people, 17.95%
Pain: 13 people, 16.67%
Depression: 12 people, 15.38%
Fatigue (feeling of tiredness): 11 people, 14.10%
Stress And Anxiety: 11 people, 14.10%
Joint Pain: 11 people, 14.10%
Mood Swings (an extreme or rapid change in mood): 9 people, 11.54%
Hair Loss: 9 people, 11.54%
Insomnia (sleeplessness): 8 people, 10.26%
Night Sweats (sweating in night): 6 people, 7.69%

What are the existing conditions these people have? *

Endometriosis (appearance of endometrial tissue outside the uterus and causing pelvic pain): 46 people, 58.97%
High Blood Pressure: 3 people, 3.85%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 3.85%
Hypersensitivity: 3 people, 3.85%
Pain: 2 people, 2.56%
Lupus Nephritis (a chronic inflammatory autoimmune disorder that may affect kidney tissue): 2 people, 2.56%
Anaphylaxis (serious allergic reaction that is rapid in onset and may cause death): 1 person, 1.28%
Antiphospholipid Syndrome (disorder that manifests clinically as recurrent venous or arterial thrombosis and/or fetal loss): 1 person, 1.28%
Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 1 person, 1.28%
Birth Control: 1 person, 1.28%

* Approximation only. Some reports may have incomplete information.

Do you take Orilissa and have Weight increased?

- Check whether Weight increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Orilissa:

Orilissa (3,314 reports)

Weight increased treatments and more:

Weight increased (279,369 reports)

Browse all side effects of Orilissa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weight increased:

Weight increased (2,886 drugs)

Browse all the conditions that are associated with Weight increased:

Weight increased (3,952 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on elagolix sodium (the active ingredients of Orilissa) and Orilissa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.